Titan Pharmaceuticals, Inc.

Equities

TTNP

US8883147055

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
7.09 USD +1.72% Intraday chart for Titan Pharmaceuticals, Inc. -3.14% -14.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule MT
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024 CI
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Titan Pharmaceuticals, Inc. Announces Board Changes CI
Titan Pharmaceuticals Appoints New Chairman of the Board MT
Titan Pharmaceuticals, Inc. Announces Board Resignations CI
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd CI
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc.. CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. for $52 million. CI
Titan Pharmaceuticals, Inc. Announces Board Changes CI
Insider Sell: Titan Pharmaceuticals MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Titan Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Sector Update: Health Care Stocks Sink on Thursday MT
Sector Update: Health Care MT
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop MT
Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022 CI
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US MT
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Declaration of Voting Results by Titan Pharmaceuticals, Inc CI
Chart Titan Pharmaceuticals, Inc.
More charts
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
More about the company
  1. Stock Market
  2. Equities
  3. TTNP Stock
  4. News Titan Pharmaceuticals, Inc.
  5. Titan Pharmaceuticals : Enters Research, Option License Agreement With MUSC Foundation